Search
Search Results
-
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit
Subcutaneous infliximab recently received approval for the treatment of various immune-mediated inflammatory diseases in Europe, following pivotal...
-
Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy
ObjectivesTo examine the outcome of infliximab treatment in patients with non-infectious paediatric uveitis who have previously failed biologic...
-
Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis
Infliximab is a monoclonal antibody specifically binding tumor necrosis factor-alpha and has been approved for the treatment of several inflammatory...
-
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Background and ObjectiveEfficacy of infliximab in children with inflammatory bowel disease can be enhanced when serum concentrations are measured and...
-
CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn’s disease
PurposeAccurately predicting the treatment response in patients with Crohn’s disease (CD) receiving infliximab therapy is crucial for clinical...
-
The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model
BackgroundTherapeutic drug monitoring (TDM) of infliximab has been shown to be a effective strategy for inflammatory bowel disease (IBD). Population...
-
Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients
BackgroundInfliximab is currently recommended as a third-line treatment for refractory sarcoidosis. Data in function of clinical phenotype are...
-
Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA
BackgroundTherapeutic drug monitoring of infliximab levels in patients with inflammatory bowel disease (IBD) optimizes patients’ treatment. The...
-
Takayasu’s arteritis associated with Crohn’s disease treated with infliximab
A 23-year-old woman presented with fever, diarrhea, bloody stools, and arthralgia that did not improve despite previous treatments and was diagnosed...
-
Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial
BackgroundJuvenile Dermatomyositis (JDM) is a rare autoimmune disorder that primarily affects muscles and skin. One of the severe complications...
-
Early Infliximab Clearance Predicts Remission in Children with Crohn’s Disease
Background and AimsChildren with Crohn’s disease have lower response rates to infliximab, lower infliximab levels, and higher infliximab clearance on...
-
Multiple ulcerative colitis-associated aseptic abscesses successfully treated with infliximab: a case report
Aseptic abscesses are rare extraintestinal manifestations of inflammatory bowel disease. Herein, we present the case of a 69-year-old female patient...
-
Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
PurposeTo compare the efficacy and safety of infliximab with that of adalimumab in the treatment of non-infectious uveitis (NIU).
Methods ...